Discovery of innovative therapeutics: today's realities and tomorrow's vision. 1. Criticisms faced by the pharmaceutical industry.

The pharmaceutical industry is facing enormous challenges, including reduced efficiency, declining innovation, key patent expirations, fierce price competition from generics, high regulatory hurdles, and a tarnished image. There is a clear need for change in the paradigms designed to address these challenges. Pharma has responded by embarking on a range of initiatives. However, along the way the industry has accrued critics whose accusations have tainted its reputation. The first part of this two-part series will discuss the criticisms that have been leveled at the pharmaceutical industry and summarize the supporting data for and against these criticisms. The second installment will focus on the current challenges facing the pharmaceutical industry and Pharma's responses to address these challenges. It will describe the industry's changing perspective and new business models for coping with the recent loss of talent and declining clinical pipelines as well as present some examples of recent drug discovery successes.

[1]  M. Shepherd,et al.  Analysis of the movement of prescription drugs to over-the-counter status. , 2015, Journal of managed care pharmacy : JMCP.

[2]  David Badcott.  Big Pharma: a former insider’s view , 2013, Medicine, health care, and philosophy.

[3]  Joan Buckley.  Pharmaceutical Marketing - Time for Change , 2004 .

[4]  R. Balkrishnan,et al.  Drug reimportation practices in the United States , 2007, Therapeutics and clinical risk management.

[5]  J. Reschovsky,et al.  More nonelderly Americans face problems affording prescription drugs. , 2009, Tracking report.

[6]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[7]  G. Nagappan,et al.  New Small Molecule Drug Discovery for Alzheimer's Disease , 2012 .

[8]  Rudolf T Hoogenveen,et al.  Lifetime Medical Costs of Obesity: Prevention No Cure for Increasing Health Expenditure , 2008, PLoS medicine.

[9]  Robert Kneller,et al.  The importance of new companies for drug discovery: origins of a decade of new drugs , 2010, Nature Reviews Drug Discovery.

[10]  Ezekiel J Emanuel,et al.  The patents-based pharmaceutical development process: rationale, problems, and potential reforms. , 2005, JAMA.

[11]  A. Maureen Rouhi,et al.  Chirality at work , 2003 .

[12]  Graham V. Lees,et al.  Drug Discovery: From Bedside to Wall Street , 2005 .

[13]  Stuart J. H. Graham,et al.  Balancing Innovation and Access: Patent Challenges Tip the Scales , 2009, Science.

[14]  M. Bradley,et al.  GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis , 2009, Annals of tropical medicine and parasitology.

[15]  Drug Truths: Dispelling the Myths About Pharma R&D , 2009 .

[16]  R. Hargreaves.  "It Ain't Over 'til It's Over" (a) -The Search for Treatments and Cures for Alzheimer's Disease. , 2012, ACS medicinal chemistry letters.

[17]  J. Moatti,et al.  Decrease in prices of antiretroviral drugs for developing countries: from political "philanthropy" to regulated markets? , 2003 .

[18]  Ben Goldacre,et al.  Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients , 2012 .

[19]  Prashant Yadav,et al.  Trends in availability and prices of subsidized ACT over the first year of the AMFm: evidence from remote regions of Tanzania , 2012, Malaria Journal.

[20]  M. Chren,et al.  Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents , 2006, Annals of Internal Medicine.

[21]  A. Stevens,et al.  The role of public-sector research in the discovery of drugs and vaccines. , 2011, The New England journal of medicine.

[22]  Chris P. Miller,et al.  A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States. , 2008, Chirality.

[23]  A. Rai.  Use Patents, Carve-Outs, and Incentives -- A New Battle in the Drug-Patent Wars , 2012, The New England journal of medicine.

[24]  T. Cymet,et al.  The Truth about Drug Companies: How They Deceive Us and What to Do about It , 2006 .

[25]  T. Khong,et al.  Making medicines evergreen , 2012, BMJ : British Medical Journal.

[26]  N. Powe,et al.  Do Drug Prices Reflect Development Time and Government Investment? , 2005, Medical care.

[27]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[28]  Joel Lexchin,et al.  The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.